MedPath

Maria Sklodowska-Curie National Research Institute of Oncology

🇵🇱Poland
Ownership
Private
Established
1951-01-01
Employees
-
Market Cap
-
Website
https://www.pib-nio.pl/

Stereotactic Management of Arrhythmia - Radiosurgery Treatment and Evaluation of Response in Ventricular Tachycardia

Not Applicable
Recruiting
Conditions
Ventricular Tachycardia
Interventions
Radiation: Stereotactic Body Radiotherapy
First Posted Date
2023-06-22
Last Posted Date
2023-10-19
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
20
Registration Number
NCT05913375
Locations
🇵🇱

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

🇵🇱

Professor Leszek Giec Upper Silesian Medical Center of the Medical University of Silesia, Katowice, Poland

The Effect of Methods of Self-regulation of Mental State on Pain Perception in the Postoperative Period in Colon Cancer Patients

Not Applicable
Recruiting
Conditions
Pain, Postoperative
Colonic Neoplasms
Hypnotherapy
Interventions
Behavioral: Autohypnosis
Behavioral: Relaxing music
First Posted Date
2023-02-01
Last Posted Date
2023-02-01
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
100
Registration Number
NCT05708872
Locations
🇵🇱

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Phase 2
Recruiting
Conditions
Adrenocortical Carcinoma
Interventions
First Posted Date
2022-10-03
Last Posted Date
2025-04-02
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
24
Registration Number
NCT05563467
Locations
🇵🇱

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie, Cracow, Poland

🇵🇱

Uniwersytecki Szpital Kliniczny W Poznaniu, Poznań, Poland

🇵🇱

Medical University Of Warsaw, Warsaw, Poland

and more 1 locations

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Phase 1
Recruiting
Conditions
Soft Tissue Sarcoma
Pulmonary Metastasis
Interventions
First Posted Date
2022-08-26
Last Posted Date
2022-08-26
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
64
Registration Number
NCT05518526
Locations
🇵🇱

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Mazovian, Poland

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Phase 3
Recruiting
Conditions
Cardiotoxicity
Interventions
First Posted Date
2022-03-08
Last Posted Date
2024-11-27
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
220
Registration Number
NCT05271162
Locations
🇵🇱

Institute of Hematology and Transfusion Medicine, Warsaw, Poland

🇵🇱

National Institute of Oncology, Warsaw, Poland

Planned Non-operative Management for Rectal Cancer

Phase 2
Conditions
Rectal Cancer
Interventions
Radiation: Radiotherapy boost
Drug: Additional consolidation chemotherapy
First Posted Date
2022-02-15
Last Posted Date
2022-02-15
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
23
Registration Number
NCT05241574
Locations
🇵🇱

M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Atherosclerosis in Chemotherapy-related Cardiotoxicity

Active, not recruiting
Conditions
Cardiotoxicity
Atherosclerosis
First Posted Date
2021-11-11
Last Posted Date
2024-11-27
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
80
Registration Number
NCT05118178
Locations
🇵🇱

National Institute of Oncology, Warsaw, Poland

Analysis of Prevalence and Risk Factors Associated With Gastroesophageal Reflux Disease and Esophagitis After Peroral Endoscopic Myotomy

Recruiting
Conditions
GERD
Achalasia
First Posted Date
2021-10-18
Last Posted Date
2021-10-18
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
100
Registration Number
NCT05080634
Locations
🇵🇱

Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Phase 2
Recruiting
Conditions
CD20-positive Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2021-06-10
Last Posted Date
2025-04-24
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
124
Registration Number
NCT04920968
Locations
🇵🇱

Oddział Hematologii i Chorób Wewnętrznych z Pododdziałem Dziennym Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o., Kraków, Poland

🇵🇱

Oddział Hematologii i Transplantacji Szpiku Centrum Onkologii Ziemi Lubelskiej im. Św. Jana z Dukli w Lublinie, Lublin, Poland

🇵🇱

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi, Łódź, Poland

and more 16 locations

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Phase 2
Recruiting
Conditions
Nasopharyngeal Cancer
Interventions
First Posted Date
2021-05-06
Last Posted Date
2025-04-24
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
32
Registration Number
NCT04875611
Locations
🇵🇱

Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w Białymstoku, Białystok, Poland

🇵🇱

Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego, Gdańsk, Poland

🇵🇱

Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach, Gliwice, Poland

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath